1-4 of 4
Fernando Ortega
Close
Sort by
Journal Articles

Central Review of PET/TC: First Spanish Experience in a Phase 2 Randomized Trial in Diffuse Large B-Cell Lymphoma (DLBCL) Patients

Mónica Coronado-Poggio, Ana Cristina Hernandez-Martinez, M. Pilar Sarandeses, Montse Cortés-Romera, Marc Simó-Perdigó, Xavier Setoain, Amanda Rotger, Carlos Grande-Garcia, González-Barca Eva, Isabel Borrego, Pilar Tamayo, Lina García-Cañamaque, Javier Banzo, González Francisco Manuel, Rodriguez Begoña, Bello Pilar, Pablo Sopena, Fernando Ortega, Ana Allende, Jaime Daumal, Jose Manuel Nogueiras, Armando López-Guillermo, Dolores Caballero
Journal: Blood
Blood (2015) 126 (23): 5042.
https://doi.org/10.1182/blood.V126.23.5042.5042
Published: 2015
Journal Articles

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Valentín García-Gutiérrez, Dragana Milojkovic, María Luisa Martín Mateos, Simone Claudiani, Concepcion Boque, PhD, Luis Felipe Casado, Gloria González, Antonio Jiménez, Alejandra Martinez Trillos, Isabel Mata Vázquez, Ángel Ramírez Payer, Alberto Álvarez Larran, Elena Amutio Díez, Abelardo Bárez García, MD, Guiomar Bautista Carrascosa, Sabela Bobillo Varela, Beatriz Cuevas Ruiz, Mª Ángeles Fernández Fernández, María del Carmen García Garay, Pilar Giraldo, MD PhD, Jose María Guinea de Castro, Natalia De Las Heras Rodríguez, MD, Nuria Hernanz Soler, Ana Iglesias Pérez, José Luis López Lorenzo, Josep Maria Martí Tutusaus, MD PhD, Rolando Omar Vallansot, Fernando Ortega Rivas, Jose Manuel Puerta, Maria Jose Ramírez Sánchez, Esperanza Romero Picos, Mario Andrés Romo Collada, Ana Rosell Mas, Silvana Saavedra Gerosa, Ana Sebrango Sadia, José Tallón Pérez, Sandra Valencia, Juan Luis Steegmann, MD
Journal: Blood
Blood (2015) 126 (23): 2786.
https://doi.org/10.1182/blood.V126.23.2786.2786
Published: 2015
Journal Articles

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

Valentín García-Gutiérrez, MD PhD, Begoña Maestro, Alejandra Martinez-Trillo, Jose Luis Lopez Lorenzo, Maria Luisa Martin Mateos, Alberto Alvarez, Ana Iglesias Pérez, Andrés Romo Collado, Angeles Fernandez, Guiomar Bautista, Angeles Portero, Beatriz Cuevas, Concepción Ruiz, Esperanza Romero, Fernando Ortega, Isabel Mata, José Tallón, Maria del Carmen García Garay, María José Ramirez Sánchez, MD, Natalia de las Heras, Pilar Giraldo, MD PhD, Sabela Bobillo, José María Guinea, Guillermo Deben, MD, Sandra Valencia, Ana Sebrango, Concepción Boqué, PhD, Juan Luis Steegmann, MD PhD
Journal: Blood
Blood (2014) 124 (21): 5523.
https://doi.org/10.1182/blood.V124.21.5523.5523
Published: 2014
Journal Articles

Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Children with Very High-Risk Acute Lymphoblastic Leukemia (VHR-ALL). Final Results of the PETHEMA ALL-93 Trial.

Josep-Maria Ribera, PhD, Juan-Jose Ortega, MD, Albert Oriol, MD, Pilar Bastida, MD, Carlota Calvo, MD, Jose-María Perez-Hurtado, MD, Maria-Elvira González-Valentin, MD, Vicky Martin-Reina, MD, Antonio Molines, MD, Fernando Ortega-Rivas, MD, Maria-Pilar Queipo, MD, Concepción Rivas, MD, Izaskun Egurbide, MD, Inmaculada Heras, MD, Concepción Poderos, MD, Eva Martínez-Revuelta, MD, Jose-Maria Guinea, MD, Eloy del Potro, MD, Guillermo Deben, MD
Journal: Blood
Blood (2005) 106 (11): 173.
https://doi.org/10.1182/blood.V106.11.173.173
Published: 2005